The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Ting‐Chao Chou, Paul Talalay · Advances in Enzyme Regulation · 1984 · 7.2K citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer

Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.9K citations

Medicine, Molecular Biology, Oncology +15

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Fortunato Ciardiello, R. Caputo, Roberto Bianco et al. · PubMed · 2000 · 938 citations

Medicine, Medicinal Chemistry, Pharmacology +17